Lister T A, Cullen M H, Brearley R B, Beard M E, Stansfeld A G, Whitehouse J M, Wrigley P F, Ford J M, Malpas J S, Crowther D
Cancer Chemother Pharmacol. 1978;1(2):107-12. doi: 10.1007/BF00254044.
Thirty previously untreated adults with diffuse histiocytic and diffuse undifferentiated lymphoma were treated with a combination of adriamycin, vincristine, prednisolone, and L-asparaginase. Complete remission was achieved in 11 out of 12 cases with stage III and 7 out of 18 cases with stage IV disease (P less than 0.005). Bone marrow infiltration, clinical central nervous system involvement, and massive intra-abdominal disease all influenced the prognosis adversely. Complete remission was followed by cranial irradiation and intrathecal methotrexate, and maintained with weekly cyclophosphamide and methotrexate and daily 6-mercaptopurine. The duration of remission was significantly longer for patients with stage III disease (the median of which has not been reached), than for patients with stage IV disease (P = 0.007). Survival was significantly longer for patients in whom complete remission was achieved than for those in whom it was not (P = 0.001), and also for patients with stage III than for those with stage IV disease (P = 0.02).
30名先前未经治疗的弥漫性组织细胞性和弥漫性未分化淋巴瘤成年患者接受了阿霉素、长春新碱、泼尼松龙和L-天冬酰胺酶联合治疗。12例Ⅲ期患者中有11例、18例Ⅳ期患者中有7例实现了完全缓解(P<0.005)。骨髓浸润、临床中枢神经系统受累和大量腹腔内病变均对预后产生不利影响。完全缓解后进行颅脑照射和鞘内注射甲氨蝶呤,并通过每周使用环磷酰胺和甲氨蝶呤以及每日使用6-巯基嘌呤来维持。Ⅲ期疾病患者的缓解持续时间(尚未达到中位数)明显长于Ⅳ期疾病患者(P = 0.007)。实现完全缓解的患者的生存期明显长于未实现完全缓解的患者(P = 0.001),Ⅲ期患者的生存期也明显长于Ⅳ期疾病患者(P = 0.02)。